

- NYHA (New York Heart Association), classification of cardiovascular disease, 1439–1440, 1440t, 1501t, 1581t
- Nylon flock exposure, 1692
- Nystagmus, 41e-1v, **210**
 congenital, 210
 etiology of, 210
 gaze-evoked, 210
 jerk, 210
 patterns of, 149, 149t
 rotary, in stimulant overdose, 473e-3
 vestibular, 210
- Nystatin
 for burn-wound infection, 166e-3
 for *Candida* infections, 350t, 351, 1332, 1344t
 for thrush, 233, 1344t
- O**
- OA. *See* Osteoarthritis (OA)
- OATB1B1 (organic anion transport protein 1B1), 38, 2000
- OATs (organic anion transporters), 431e-1, 431e-2f
- Obesity, **2392**
 body mass index in, 98e-1t, 2392
 breast cancer risk and, 524
 cancer and, 415e-6, 476
 central adiposity in, 6e-4, 2449
 comorbid conditions, 2392, 2394t
 asthma, 1670–1671
 bone and joint disorders, 415e-6, 2229
 cardiovascular disease, 266e-4, 290e-1t, 290e-2, 291e-9, 415e-6, 1563, 1587
 cutaneous disorders, 415e-6
 diabetes mellitus, 82, 415e-6, 2401, 2401t, 2404–2405
 erectile dysfunction, 326
 gallstones, 415e-6
 hypertension, 415e-6, 1612, 1622
 hypogonadotropic hypogonadism, 2364–2365
 hypothalamic disorders, 2264
 lipoprotein disorders, 2438, 2439
 liver disease, 415e-6, 2054, 2055, 2057
 pulmonary disease, 415e-6
 reproductive disorders, 415e-6
 sleep apnea and, 415e-6
 definition of, 98e-1t, 415e-1
 drug-induced, 2392
 dyspnea in, 47e-2
 etiology of, **415e-3**
 craniopharyngioma in, 415e-4
 Cushing's syndrome in, 415e-4
 energy expenditure in, 415e-5
 food intake in, 415e-5
 genetic syndromes, 415e-3–4, 415e-4t
 genetic vs. environmental factors in, 415e-3
 hypothalamic disorders in, 415e-4
 hypothyroidism in, 415e-4
 insulinoma in, 415e-4
 leptin in, 415e-4t, 415e-5
 evaluation of, 415e-1, 415e-1f, 2392–2393, 2393t, 2394t
 fatigue and, 152
 global burden of, 17, 266e-4
 gut microbiota and, 86e-8–9
 high-altitude travel and, 476e-5
 history focused on, 2392
 in metabolic syndrome, 2450, 2450t, 2453
 oral contraceptives use in, 2391
 physical fitness and, 2392
 physiology of, 415e-2, 415e-2f
 pregnancy and, 48
 prevalence of, 415e-1–2, 2254t
 pulmonary function values in, 306e-5, 306e-5f
 screening/testing for, 29t, 2254t
 treatment of, **2393**
 bariatric surgery, 2398, 2398f
 behavioral therapy, 2396
 diet therapy, 2394–2396
 exercise program, 2396
 goal of, 2393–2394
 in metabolic syndrome, 2453
- pharmacotherapy, 2396–2397
 readiness to change and, 2392–2393
 selection of, 2395f, 2395t
 upper body, 6e-4
 in women, 6e-4
- Obesity hypoventilation syndrome, 415e-6, 1722
ob gene, 415e-4, 415e-5
- Obinutuzumab, 103e-21, 103e-21t, 703
- Object recognition, 182
- Observational data, 25
- Obsessive-compulsive disorder (OCD), **2713**
- Obstetric neuropathies, 463e-5
- Obstructive sleep apnea/hypopnea syndrome (OSAHS)
 cardiovascular effects of, 1726
 clinical features of, 1724–1725
 daytime sleepiness in, 188, 1723, 1726
 definition of, 1723
 diagnosis of, 188t, 1721, 1721t, 1725, 1725t
 epidemiology of, 1724
 fatigue and, 152
 in heart failure, 1514
 hypertension and, 1619, 1725
 in metabolic syndrome, 2452
 obesity and, 415e-6, 1620, 1724
 pathophysiology of, 306e-5, 1723–1724, 1723f
 polysomnography in, 1725, 1726f
 pulmonary hypertension in, 1657
 quality of life in, 1726
 risk factors for, 1724
 severity scale for, 1725t
 treatment of, 188t, 1620t, 1727, 1727t
- Occam's razor, 19
- Occipital lobe stroke, 204
- Occipital nerve stimulation, 2596
- Occipitotemporal network, 182
- Occupational illness. *See also* Health care workers
 animal bite-wounds, 167e-1–2
 asthma, 1670, 1671
 contact dermatitis, 345
 hand eczema, 346
 hearing loss, 224–225, 225t
 lung disease, 1662
 asbestos-related. *See* Asbestos-related disease
 categories of, 1688t
 characteristics of agents causing, 1688
 chest imaging in, 1687–1688
 chronic beryllium disease, 1691
 coal worker's pneumoconiosis, 1690
 COPD, 1703
 disability assessment in, 1693
 exposure assessment in, 1687
 history in, 1687
 hypersensitivity pneumonitis. *See* Hypersensitivity pneumonitis
 incidence of, 1687
 inorganic dusts, 1688t, 1691
 organic dusts, 1688t, 1691
 pulmonary function tests in, 1687
 silicosis, 1689–1690, 1690f
 toxic chemicals, 1691–1692, 1692t
 in World Trade Center rescuers, 1692
 osteoarthritis, 2229
 shift-work disorder, 194
- OCD (obsessive-compulsive disorder), **2713**
- OCG (oral cholecystography), 2078
- Ochrobactrum* spp., 183e-3, 194e-1
- Ochronosis, 434e-4
- Ochronotic arthritis, 434e-4
- Ochronotic pigmentation, 436e-7f
- Ocrelizumab, 2672
- OCT (optical coherence tomography), 1668
- Octopus envenomation, 2740
- Ocreotide
 for acromegaly, 2271
 adverse effects of, 567, 574, 2271
 for carcinoid syndrome, 272, 565, 567
 for chemotherapy-related diarrhea, 103e-16, 103e-25
 for dumping syndrome, 1926
 in end-of-life care, 61
 for gastrinoma, 2337
- for glucagonoma, 570
 for hepatorenal syndrome, 1810
 for hypomotility of small bowel, 2164
 for insulinoma, 569, 2434
 for intestinal pseudoobstruction, 260t, 261
 for NETs, 574
 for oncogenic osteomalacia, 612
 for postprandial orthostatic hypotension, 2644
 radiolabeled, 575
 for somatostatinoma, 570
 structure of, 566f
 for thymoma, 123e-2
 for thyroid dermopathy, 2298
 for variceal bleeding, 277, 2064
 for vascular ectasias, 277
 for VIPoma, 571
 for ZES, 1929
- Ocular alignment, 197
- Ocular disorders, **195**. *See also* Optic neuritis; Visual loss
 acne rosacea and, 352
 in ankylosing spondylitis, 2171
 in Behçet's syndrome, 200, 2194
 in cat-scratch disease, 1079, 1081f, 1081t
 in diabetes mellitus. *See* Diabetes mellitus (DM), complications of; Diabetic retinopathy
 in granulomatosis with polyangiitis, 2184
 at high altitudes, 476e-4
 in IBD, 1958
 infections. *See also* Conjunctivitis; Keratitis; Retinitis
Candida, 1343, 1343f, 1345
 gonococcal, 1006, 1009t
L. loa. *See* *Loa loa* (African eye worm)/ loiasis
Nocardia, 1086
Onchocerca, 1421
P. aeruginosa, 1045t, 1046
T. gondii, 1402, 1404
Toxocara, 1411
 in lepromatous leprosy, 1125
 in Marfan syndrome, 2513
 in MS, 2663
 in myasthenia gravis, 2701–2702
 in osteogenesis imperfecta, 2508
 in relapsing fever, 1147
 in relapsing polychondritis, 2203
 in sarcoidosis, 2207, 2656
 in Sjögren's syndrome, 2166
 SLE and, 2129t, 2131
 trachoma, 1172
 in tularemia, 1068
- Ocular flutter, 41e-1v, 211
- Ocular lubricants, 199
- Ocular movements, 41e-1v, 195
 assessment of, 197
 “bobbing,” 1775
 in coma, 1774–1775, 1774f
 “dipping,” 41e-1v, 1775
 in dizziness evaluation, 149
- Oculocephalic reflexes, 1775, 2604
- Oculomotor ataxia, 181
- Oculomotor nerve, 2537
- Oculomotor nerve palsy, 195, 208
- Oculopharyngeal dystrophy, 208, 462e-5t, 462e-11
- Odanacatib, 2503
- Odontoid fracture, 441e-33f
- Odynophagia, 254, 262, 533, 1901, 1909
- Ofatumumab, 103e-21, 103e-21t, 703
- Office of Research on Women's Health (NIH), 6e-1
- Ofloxacin
 for *C. trachomatis* infection, 1171
 for enteric fever, 1052
 for leprosy, 1127
 for pelvic inflammatory disease, 878
 for plague, 1075
- Ogilvie's disease. *See* Intestinal pseudoobstruction (Ogilvie's disease)
- Oka. *See* Varicella vaccine
- OKT3, 253t, 372e-30, 2071